Mainz Biomed Director Signals Confidence with Strategic $6 Million Capital Injection

Mainz, Tuesday, 3 March 2026.
Director David Lazar has executed a high-stakes $6 million investment strategy in Mainz Biomed, utilizing preferred shares with aggressive conversion ratios to fund a pivot toward U.S. pancreatic cancer screening. This capital injection, confirmed in March 3 filings, is explicitly tied to future board control and stockholder approvals, marking a critical turning point for the diagnostics firm.